Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Consensus Rating of “Hold” from Brokerages

Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) have received a consensus recommendation of “Hold” from the eight ratings firms that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, four have issued a hold rating and three have issued a buy rating on the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $6.1429.

Several brokerages have issued reports on ZNTL. Mizuho assumed coverage on shares of Zentalis Pharmaceuticals in a research note on Friday, July 17th. They issued an “outperform” rating and a $8.00 price target on the stock. Guggenheim upped their price target on shares of Zentalis Pharmaceuticals from $6.00 to $10.00 and gave the stock a “buy” rating in a research report on Friday, April 10th. Wall Street Zen upgraded shares of Zentalis Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Sunday, May 31st. Weiss Ratings reissued a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a report on Monday, July 6th. Finally, HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Zentalis Pharmaceuticals in a research note on Friday, May 22nd.

Zentalis Pharmaceuticals Price Performance

NASDAQ ZNTL opened at $5.01 on Wednesday. The stock’s 50-day moving average is $4.14 and its 200-day moving average is $3.42. Zentalis Pharmaceuticals has a one year low of $1.21 and a one year high of $6.95. The firm has a market cap of $356.66 million, a P/E ratio of -2.90 and a beta of 1.92.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.01). Equities analysts anticipate that Zentalis Pharmaceuticals will post -1.92 EPS for the current year.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

A number of large investors have recently made changes to their positions in ZNTL. Sivia Capital Partners LLC acquired a new stake in Zentalis Pharmaceuticals during the 4th quarter worth approximately $27,000. CTC Alternative Strategies Ltd. acquired a new position in Zentalis Pharmaceuticals in the 1st quarter valued at $29,000. Qube Research & Technologies Ltd acquired a new position in Zentalis Pharmaceuticals in the 2nd quarter valued at $37,000. Voleon Capital Management LP bought a new position in Zentalis Pharmaceuticals during the 3rd quarter worth $41,000. Finally, State of Wyoming bought a new position in Zentalis Pharmaceuticals during the 1st quarter worth $67,000.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.